Raises EUR 1 Million Seed Capital to Advance Personalized Treatment for High Cholesterol
Summary
HELSINKI, Finland (October 8th, 2024) MONCYTE Health diagnostics, developing proprietary technology to optimize treatment and prevention of cardiovascular disease, has closed a EUR 1 million seed round to fund its go-to-market strategy. The readouts are derived from white blood cells, including monocytes, which play key roles in atherosclerotic plaque formation and inflammation, linking directly to cardiovascular risk. We believe that personalized approaches for more effective lipid-lowering therapy and better insights into how immune cells accelerate plaque development can prevent heart attack and stroke more effectively.Investing in MONCYTE Health was a compelling choice for us, driven by the exceptional expertise of the team and initial traction of the market. We are excited to embark on this journey together and make an impact, said Maria Severina, CEO and Founder at Almaral.MONCYTE Health is laser focused on high cholestrol, the leading risk factor for cardiovascular diseases. The team, led by Tamara and CSO and co-founder, Simon Pfisterer, has spent years in Helsinki University in creating a unique technology, IP, and deep understanding in cellular mechanisms underlying cardiovascular disease progression.
Funding
Review available funding amount, funding date, investors, and linked company information related to Raises EUR 1 Million Seed Capital to Advance Personalized Treatment for High Cholesterol in the interactive ISVWorld profile.